Investigational iptacopan Phase 3 study demonstrates clinically meaningful proteinuria reduction in patients with IgA nephropathy.
Novartis today announced positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study at 9 months. Iptacopan, an investigational factor B inhibitor targeting the alternative complement pathway, demonstrated superiority versus placebo in proteinuria (protein in urine)…